LaNova Medicines Limited
18
9
10
0
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 100/100
27.8%
5 terminated/withdrawn out of 18 trials
0.0%
-86.6% vs industry average
6%
1 trials in Phase 3/4
0%
0 of 0 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (18)
A Phase I/II Study of LM-364 as a Single Agent or in Combination With Anti-tumor Therapy in Patients With Advanced Solid Tumors
Role: lead
A Study of LM-108 as Monotherapy or in Combination With Antitumor Therapies in Subjects With Advanced Solid Tumors
Role: lead
A Phase I/II Study of LM-2417 in Subjects With Advanced Solid Tumours
Role: lead
A Study of LM-168 Combined With Other Anti-tumor Treatments in Participants With Advanced Solid Tumors
Role: lead
A Study of LM-364 as a Single Agent or in Combination With Anti-tumor Therapy in Patients With Advanced Solid Tumors
Role: lead
LM-108 in Combination With Toripalimab Versus Paclitaxel Injection for the Treatment of Subjects With CCR8-Positive Gastric and Gastroesophageal Junction Adenocarcinoma
Role: lead
Phase II Study of LM-24C5
Role: lead
A Study of LM-350 in Subjects With Advanced Solid Tumours
Role: lead
A Study of LM-168 as a Single Agent or in Combination With Toripalimab in Subjects With Advanced Solid Tumours
Role: lead
A Study of LM-24C5 For Advanced Solid Tumors
Role: lead
Study of LM-299 in Subjects Advanced Malignant Tumors
Role: lead
A Study of LM-108 in Combination With Toripalimab in Subjects With Advanced Solid Tumours
Role: lead
A Phase I/II Study of LM-101 Injection in Patients With Advanced Malignant Tumors
Role: lead
Study of LM-305 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) and Other Plasma Cell Diseases
Role: lead
Study of LM-108 as a Single Agent or in Combination With Pembrolizumab in Subjects With Advanced Solid Tumours
Role: lead
Study of LM-061 in Subjects in Advanced Tumors
Role: lead
A Clinical Study Preliminary Efficacy of LM-061 Tablet in Subjects With Advanced Tumours
Role: lead
Study of LM-102 in Subjects in Advanced Tumors
Role: lead
All 18 trials loaded